BJMO - volume 15, issue 2, march 2021
K. Van Baelen MD, N. Van den Rul MD, S. Marquette MD, L. Vansteelant MD, J. Mebis MD, C. Thywissen MD, A.-S. Vliegen MD, L. Noé MD, M. Drijkoningen MD, PhD, G. Orye MD
In clinical practice, the diversity in the surgical management of the axilla after neo-adjuvant chemotherapy (NACT) for node positive patients is huge. Given the morbidity of axillary lymph node dissection (ALND), a trend to perform a less invasive technique is seen in both literature and clinical practice. There are three major techniques: 1) sentinel lymph node biopsy (SLNB), 2) guided removal of lymph nodes that were positive prior to NACT, and 3) Targeted Axillary Dissection (TAD) which is a combination of the previous two techniques. Criteria for patients eligible for these techniques vary widely and oncological safety cannot always be guaranteed. With this report, we aim to introduce TAD in a safe way into the clinical practice.
(BELG J MED ONCOL 2021;15(2):69-74)
Read moreBJMO - volume 12, issue 3, february 2018
J. Robijns PhD, S. Censabella , S. Claes , Luc Pannekoeke , Lore Bussé , D. Colson , Iris Kaminski , A. Maes MD, P. Bulens MD, M. Brosens , L. Noé MD, Ivo Lambrichts , A. Timmermans , V. Somers , J. Mebis MD
BJMO - volume 12, issue 3, february 2018
J. Mebis MD, S. Censabella , S. Engels , Guy Orye , S. Marquette MD, C. Van Narsenille , L. Vansteelant MD, L. Noé MD, A. Maes MD, P. Bulens MD, D. Luyten MD, E. Joosens MD
BJMO - volume 12, issue 3, february 2018
J. Mebis MD, S. Censabella , S. Engels , C. Van Narsenille , Guy Orye , S. Marquette MD, L. Vansteelant MD, L. Noé MD, A. Maes MD, P. Bulens MD, D. Luyten MD, E. Joosens MD
BJMO - volume 11, issue 8, december 2017
J. Robijns PhD, S. Censabella , P. Bulens MD, A. Maes MD, L. Noé MD, M. Brosens , L. Van den Bergh MD, PhD, S. Claes , J. Mebis MD
Photobiomodulation therapy is based on the application of visible and/or (near-)infrared light on the target tissue. We performed a review of 34 articles on the use of photobiomodulation therapy in the management of cancer related lymphoedema, oral mucositis, radiodermatitis, chemotherapy-induced peripheral neuropathy, osteonecrosis of the jaw, and xerostomia/hyposalivation. The findings suggest that photobiomodulation therapy is a promising option for the management of these cancer therapy-related side effects.
(BELG J MED ONCOL 2017;11(8):364–374)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
